Shilpa Gupta
机构：Holy Spirit Hospital, Cleveland Clinic, Vels University, ACS Medical College and Hospital, San Jose State University · ORCID：0000-0002-8775-503X
发表论文 582 篇 · 总被引 16478 次 · h-index 52
代表论文
- Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer (2026 · New England Journal of Medicine · 被引 103)
- Pan-Asian subgroup analysis of EV-302/KEYNOTE-A39: a phase 3 study to evaluate enfortumab vedotin and pembrolizumab in patients with untreated advanced urothelial carcinoma (2026 · International Journal of Clinical Oncology · 被引 6)
- [177Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial (2026 · The Lancet · 被引 4)
- Efficacy of Enfortumab Vedotin After Platinum Chemotherapy and Pembrolizumab in Metastatic Urothelial Carcinoma: A Multicenter Real-World Analysis of the ARON-2EV Cohort (2025 · European Urology Open Science · 被引 3)
- A Computational Pathology Model to Predict Docetaxel Benefit in Localized High-Risk and Metastatic Prostate Cancer (2025 · Clinical Cancer Research · 被引 2)
- Genomic landscape of TP53 Y220C–mutated clinically advanced prostate carcinoma (CAPC) (2026 · International Journal of Cancer Care and Delivery)